Hybrid outsourcing model

Offshore drug discovery support

A hybrid outsourcing model offers a compelling strategic advantage in drug discovery, combining the proximity and deep domain expertise of the Domainex UK based team with the significant cost efficiencies and resource capacity of offshore partners.

A truly flexible solution

The blended approach moves beyond the traditional binary choice of onshore versus offshore, creating a flexible, "best-of-both-worlds" solution tailored to your specific needs. The primary benefit is cost control; by allocating resource-intensive, routine tasks to lower-cost regions, companies can significantly reduce R&D expenditures. Simultaneously, critical project management and complex research is handled by Domainex UK-based experts, ensuring quality and clear communication.

Accelerate drug discovery timelines

This model enhances operational resilience and can accelerate timelines. By leveraging our global network, clients mitigate the risks of capacity constraints in a single location. This is particularly valuable in the fast-paced biotech and pharma sectors where speed to market is a crucial competitive edge. The result is an optimised research pipeline that balances financial prudence with scientific rigor and speed, making the hybrid model a cornerstone strategy for efficient and effective preclinical drug discovery in a global landscape.

Our expert project managers will seamlessly manage the network of offshore providers on your behalf with either our alliance partners or your preferred supplier. Speak to a member of our team to find out more.

This testimonial is in support of Domainex’s integrated drug-discovery services. My first interaction with Domainex was in 2018, where we had a yearlong collaboration solely focused on the synthesis of beyond-rule-of-5 compounds. The team demonstrated a high level of tenacity and productivity and enabled significant progress on the project as evidenced by milestone payments from our partner. Given the positive experience, I’ve returned to Domainex for a significantly larger collaboration, again working with BRO5 chemistry and integrating degrader and structural biology platforms that are Domainex core areas of expertise. The quality of science, innovation, organization, and tenacity of the team is very high- across all functions of synthetic and medicinal chemistry, structural biology and especially in vitro biology, where the team have quickly developed a plethora of complex assays. Additionally, the ability of the team to organize logistics and integrate with our own resources such as CROs and consultants has made the process seamless in execution.

Bruce Clapham

Executive Director, Medicinal Chemistry, evommune

Working with Domainex is a pleasure! The Domainex team have been integral to our project team - providing biology, crystallography and chemistry expertise in drug discovery that is highly valued by Sitryx. Their professionalism, friendliness, open communication style and approachability has meant we’ve been able to navigate our way through complex biology and challenging medicinal chemistry with maximum engagement and minimal frustration. Domainex employees have gone the extra-mile to accommodate difficult requests and have worked collaboratively and exhaustively to give our project the best possible chance of success.

Domainex team has demonstrated exceptional levels of customer service during our collaboration. Open communication with Domainex leadership has been a constant feature, ensuring alignment between resources allocation and project’s goals and timelines.

Peter Bunyard and Alessandro Mazzacani

Director of Immunology and R&D project Manager, Sitryx Therapeutics